A California-based lawyer, Attorney Michael Lin Baum has successfully led numerous wrongful death and personal injury cases through his law firm, Baum Hedlund Aristei & Goldman, where he has served as managing partner since 1985. Possessing a significant knowledge of biomedical research, clinical trials, statistics, and the pharmaceutical industry, Michael Lin Baum has also successfully worked closely with experts on complicated scientific issues related to Baum Hedlund’s pharmaceutical litigation. In previous litigation, Baum Hedlund investigated a suicide case involving a deceased who was taking Paxil. Paxil is a registered trademark of GlaxoSmithKline (GSK). During the investigation, Baum Hedlund reviewed clinical trial data associated with the drug and found out that the study is actually flawed. Paxil Study 329 is a work of multiple accredited researchers, which subjected the validity of the report to no questioning. In actuality, some crucial information is missing in the publication and the study's conclusion is far from the truth. When Baum Hedlund consulted one of the lead authors, he admitted that he failed to scrutinize the raw data gathered from the clinical trial. Rather, the author had evaluated the summary presented to him. A subsequent comprehensive study of the drug was conducted in 2015, the result of which revealed that the drug is not effective as thought. This contradicts the claim in the result of Paxil Study 329. The comprehensive study also found that the drug may aggravate suicidal thoughts among adolescents.

1. Michael Lin Baum

2. A California-based lawyer, Attorney Michael Lin Baum has successfully
led numerous wrongful death and personal injury cases through his law
firm, Baum Hedlund Aristei & Goldman, where he has served as
managing partner since 1985. Possessing a significant knowledge of
biomedical research, clinical trials, statistics, and the pharmaceutical
industry, Michael Lin Baum has also successfully worked closely with
experts on complicated scientific issues related to Baum Hedlund’s
pharmaceutical litigation.

3. In previous litigation, Baum Hedlund investigated a suicide case
involving a deceased who was taking Paxil. Paxil is a registered
trademark of GlaxoSmithKline (GSK). During the investigation, Baum
Hedlund reviewed clinical trial data associated with the drug and found
out that the study is actually flawed. Paxil Study 329 is a work of multiple
accredited researchers, which subjected the validity of the report to no
questioning. In actuality, some crucial information is missing in the
publication and the study's conclusion is far from the truth.

4. When Baum Hedlund consulted one of the lead authors, he admitted that
he failed to scrutinize the raw data gathered from the clinical trial. Rather,
the author had evaluated the summary presented to him.

5. A subsequent comprehensive study of the drug was conducted in 2015,
the result of which revealed that the drug is not effective as thought. This
contradicts the claim in the result of Paxil Study 329. The comprehensive
study also found that the drug may aggravate suicidal thoughts among
adolescents.